Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Human natural killer cell preparation is an adoptive cell therapy being developed by Shanghai Life Science & Technology (莱馥生命科技) for the treatment of solid tumors. As part of the company's 'Universal Somatic Cell Drug' category, this therapy utilizes natural killer (NK) cells, which are innate immune effector cells capable of identifying and lysing malignant cells without prior sensitization. NK cells exert their anti-tumor effects through the release of cytotoxic granules containing perforin and granzymes, as well as through the expression of death ligands like TRAIL and FasL. The preparation is designed to bolster the patient's innate immune response to overcome the immunosuppressive microenvironment typically found in solid malignancies.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Human natural killer cell preparation (Shanghai Life Science & Technology).